bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
2024年11月4日 - 10:00PM
ビジネスワイヤ（英語）
Dr. William Bauta, bioAffinity Senior Vice
President of Research and Development and former Associate Director
of Science at Genzyme and Ilex, steps into new role with the
retirement of Dr. Vivienne Rebel
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW)
(“bioAffinity” or the “Company”), a biotechnology company
focused on the need for noninvasive tests for the detection of
early-stage lung cancer and other lung diseases, today announced
that William Bauta, Ph.D., has been appointed Chief Science
Officer. Before joining bioAffinity in 2016 as Senior Vice
President of Research and Development, Dr. Bauta was the Associate
Director of Science at Genzyme Corporation and held a similar
position at Ilex Products, Inc., where he was responsible for the
discovery, development and FDA approval of therapeutics in the
companies’ pipelines, and Manager of Medicinal and Process
Chemistry at Southwest Research Institute.
Dr. Bauta is responsible for multiple Company inventions and
patents supporting bioAffinity’s diagnostic and therapeutic
advancements, including improvements to optimize CyPath® Lung, the
Company’s noninvasive test to detect early-stage lung cancer, that
both improved performance and cut costs. His discoveries have
expanded the Company’s patent portfolio and added to a growing list
of publications. In addition to bioAffinity patents on which he is
a named inventor, he holds multiple healthcare-related patents and
has published in more than a dozen scientific journals, including
the journal Science.
“Dr. Bauta brings both scientific rigor and business acumen to
the CSO position as we accelerate the commercial rollout of our
CyPath® Lung test and expand our development pipeline. He will work
with an exceptional scientific team who developed our high
throughput, automated diagnostic platform to accurately analyze the
lung microenvironment, allowing us to advance new technologies that
can detect early-stage diseases. He is focused on making our
products important steps in the care pathway for diagnosing
early-stage disease,” bioAffinity President and CEO Maria Zannes
said.
Dr. Bauta earned his Ph.D. from the University of Chicago where
he received fellowships from the National Science Foundation and
the American Chemical Society. His post-doctoral studies were at
the University of Texas at Austin under a National Institutes of
Health fellowship.
Dr. Bauta succeeds Vivienne I. Rebel, M.D., Ph.D. who retired
from her position on Oct. 31, 2024, as Executive Vice President and
Chief Science and Medical Officer. Dr. Rebel joined the Company in
2016 and led the research and development of CyPath® Lung.
“We wish Dr. Rebel the very best in retirement,” said Zannes.
“Vivienne has made an indelible mark on us all. Her scientific
precision and innovative spirit will remain a hallmark of
bioAffinity Technologies.”
About CyPath® Lung
CyPath® Lung uses proprietary advanced flow cytometry and
artificial intelligence (AI) to identify cell populations in
patient sputum that indicate malignancy. Automated data analysis
helps determine if cancer is present or if the patient is
cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that
is preferentially taken up by cancer and cancer-related cells.
Clinical study results demonstrated that CyPath® Lung had 92%
sensitivity, 87% specificity and 88% accuracy in detecting lung
cancer in patients at high risk for the disease who had small lung
nodules less than 20 millimeters. Diagnosing and treating
early-stage lung cancer can improve outcomes and increase patient
survival. For more information, visit www.cypathlung.com.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for
noninvasive diagnosis of early-stage cancer and other diseases of
the lung and broad-spectrum cancer treatments. The Company’s first
product, CyPath® Lung, is a noninvasive test that has shown high
sensitivity, specificity and accuracy for the detection of
early-stage lung cancer. CyPath® Lung is marketed as a Laboratory
Developed Test (LDT) by Precision Pathology Laboratory Services, a
subsidiary of bioAffinity Technologies. For more information, visit
www.bioaffinitytech.com.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. These forward-looking
statements are based upon current estimates and assumptions and
include statements regarding accelerating the commercial rollout of
our CyPath® Lung test, expanding our development pipeline,
advancing new technologies that can detect early-stage diseases,
and making our products important steps in the care pathway for
diagnosing early-stage disease. These forward-looking statements
are subject to various risks and uncertainties, many of which are
difficult to predict, that could cause actual results to differ
materially from current expectations and assumptions from those set
forth or implied by any forward-looking statements. Important
factors that could cause actual results to differ materially from
current expectations include, among others, the ability of the
Company to accelerate the commercial rollout of its CyPath® Lung
test, expand its development pipeline, advance new technologies
that can detect early-stage diseases and the other factors
discussed in the Company’s Annual Report on Form 10-K for the year
ended December 31, 2023, and its subsequent filings with the SEC,
including subsequent periodic reports on Forms 10-Q and 8-K. Such
forward-looking statements are based on facts and conditions as
they exist at the time such statements are made and predictions as
to future facts and conditions. While the Company believes these
forward-looking statements are reasonable, readers of this press
release are cautioned not to place undue reliance on any
forward-looking statements. The information in this release is
provided only as of the date of this release, and the Company does
not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241104703672/en/
bioAffinity Technologies Julie Anne Overton Director of
Communications jao@bioaffinitytech.com
Investor Relations Dave Gentry RedChip Companies Inc.
1-800-RED-CHIP (733-2447) or 407-491-4498 BIAF@redchip.com
bioAffinity Technologies (NASDAQ:BIAF)
過去 株価チャート
から 10 2024 まで 11 2024
bioAffinity Technologies (NASDAQ:BIAF)
過去 株価チャート
から 11 2023 まで 11 2024
